A Phase 2 Open Label Single Arm Study Evaluating the Safety, Efficacy, and Pharmacokinetics of KX2-391 in Patients with Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy